Since the discovery of the novel coronavirus (SARS-Co-V-2) in December 2019, multiple characteristics have been reported, as our understanding of this new disease MESHD unfolds. One such association is its tendency to cause thromboembolic events, particularly venous thromboembolism MESHD thromboembolism HP (1,2). In a four-week period during the initial spread of COVID-19 at a 300 bed community hospital in western Massachusetts, 23 patients who were PCR positive for SARS-CoV-2 RNA required treatment in either the intensive care unit (ICU) or intermediate/step-down unit (SDU). All patients were treated with standard DVT prophylaxis from the time of admission, except for two patients who were on full anticoagulation for chronic atrial fibrillation MESHD atrial fibrillation HP. Of the 23 patients, 7 (30%) were diagnosed with acute, clinically significant, pulmonary embolism MESHD pulmonary embolism HP (PE). Four of the 7 manifested evidence of acute cor pulmonale HP, one of whom succumbed as a direct consequence of a massive PE. Other markers were reviewed in the 7 patients to identify trends that could allow for early suspicion of PE in COVID-19 patients. Although D-dimer tended to rise during the hospitalization relative to the control group, the results were inconsistent, and there were no other meaningful distinguishing features between the groups at the time of admission.